The company's recent advance follows its return to profitability in the second quarter of FY27, generating a net profit of ₹19.5 crore compared to a ₹9.2 crore loss a year earlier. Top-line performance supported the rebound, with operational revenue rising 7.4% year-on-year to ₹507 crore and EBITDA increasing 10% to ₹33 crore. Having climbed nearly 24% from its recent low of ₹205.10 across 14 trading sessions, market experts are watching for a sustained breakout above immediate resistance to extend the run.
Key points
Technical analysts identify key downside support for the equity within the ₹230 to ₹235 z…: Technical analysts identify key downside support for the equity within the ₹230 to ₹235 zone.
Overcoming immediate resistance between ₹256 and ₹260 could trigger target advances towar…: Overcoming immediate resistance between ₹256 and ₹260 could trigger target advances toward ₹270 to ₹288.
The stock has advanced nearly 24% from its recent low of ₹205.10 over the span of 14 trad…: The stock has advanced nearly 24% from its recent low of ₹205.10 over the span of 14 trading sessions.
Sources checked by our analysis pipeline: 1
Indoco Remedies shares rallied over 13% on Wednesday, 18 November, even as the broader stock market remained subdued. The pharmaceutical stock has gained 13.21% over the past week and 16.25% over the past two weeks, extending its recent recovery.
The stock opened at an intraday low of ₹226.75 apiece before climbing to a high of ₹254.75 during the session.
The sharp rally has brought the stock into focus, with technical experts pointing to improving momentum, strong volumes and crucial resistance levels that could determine its next move.
Sudeep Shah, Head of Technical and Derivatives Research at SBI Securities, said the stock has rebounded nearly 24% from its low of ₹205.10 in just 14 trading sessions. Following the recovery, it has moved above its key moving averages, signalling an improvement in near-term momentum.
However, Shah cautioned that the broader trend remains range-bound, with the stock having consolidated within the ₹205–288 range over the past few months.
According to him, the ₹256–260 zone is likely to act as immediate resistance. A decisive breakout above ₹260 could extend the ongoing rally towards ₹288,…
Rising medical costs are placing heavy pressure on insurance providers while concurrently driving gains for LivaNova stock. The ongoing surge in healthcare expenditures continues to present a challenge for insurers, even as it boosts the medical technology company's market performance.
The data storage provider has experienced a steep monthly sell-off that is dividing market watchers between potential bargain opportunities and risks of a prolonged downturn. Investors are assessing whether the contraction represents an attractive entry point or an indication of broader structural pressures. This sharp decline places renewed scrutiny on the company's operational trajectory and near-term market demand.
Quantitative investment systems frequently look beyond standard valuation metrics when evaluating major financial institutions. Although the investment bank is valued at a specific multiple, several algorithmic frameworks determined the shares were not suitable for selection. This indicates that automated screening strategies are prioritizing factors outside of conventional pricing multiples.